GlassScriptPhysician profile
Keith W Harris
NPI 1114026853
$831,891.38
in general payments reported to CMS, 2019-2025
42 companies · $227K in 2025
The $227K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $39K · 2021: $48K · 2022: $114K · 2023: $182K · 2024: $104K · 2025: $227K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $355K · Honoraria: $75K · Travel and Lodging: $51K · Food and Beverage: $20K · Consulting Fee: $12K · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $354,891.43 |
| Honoraria | $74,500.00 |
| Travel and Lodging | $50,876.02 |
| Food and Beverage | $20,216.81 |
| Consulting Fee | $11,625.00 |
| Education | $175.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $411,819.84 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $195,177.13 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $105,398.31 | 2019-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $102,594.52 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,836.68 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Hill-Rom Company, INC | $875.00 | 2021 | |
| Mylan Specialty L.P. | $870.87 | 2019-2024 | Yupelri |
| Grifols Shared Services North America, INC. | $820.00 | 2023 | Prolastin-C Liquid |
| Electromed, INC. | $520.88 | 2019-2025 | Smartvest |
| Genzyme Corporation | $479.13 | 2019-2025 | |
| Insmed, INC. | $468.76 | 2021-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $336.83 | 2019-2025 | Dupixent |
| Advanced Respiratory, INC | $242.25 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $214.44 | 2022-2024 | Purified Cortrophin Gel |
| Baxter Healthcare | $173.25 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $164.02 | 2024-2025 | Zemaira |
| Sunovion Pharmaceuticals INC. | $156.56 | 2019 | |
| Fisher & Paykel Healthcare INC | $148.55 | 2020-2021 | |
| Philips North America LLC | $145.01 | 2019-2024 | (Ak6) Vest Therapy |
| Viatris Specialty LLC | $142.59 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $137.39 | 2019-2025 | Uptravi, Opsumit |
| Harmony Biosciences LLC | $129.60 | 2020-2025 | |
| Allergan, INC. | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $116.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $115.65 | 2019-2025 | Zerbaxa, Keytruda, Dificid |
| Amgen INC. | $113.60 | 2022-2025 | Tezspire |
| Pfizer INC. | $107.07 | 2019-2025 | |
| Genentech USA, INC. | $91.90 | 2019 | |
| Axsome Therapeutics, INC. | $66.37 | 2023-2025 | Sunosi |
| Nabriva Therapeutics, Plc | $54.89 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.56 | 2024 | Glassia |
| 3b Medical, INC. | $29.36 | 2025 | Luna |
| Csl Behring | $27.30 | 2020 | |
| Boston Scientific Corporation | $25.19 | 2022 | |
| Inogen, INC. | $23.03 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Optinose US, INC. | $18.93 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.92 | 2021 | |
| Olympus America INC. | $16.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.33 | 2021 | |
| Abbvie INC. | $13.23 | 2021 | |
| Shire North American Group INC | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.